Peer-reviewed veterinary case report
Treating dog Cushing's disease with mitotane or trilostane
By Reine, Nyssa J·Published in Clinical techniques in small animal practice·2007·Animal Medical Center, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Medical management of pituitary-dependent hyperadrenocorticism: mitotane versus trilostane.
- Species:
- dog
Plain-English summary
A dog diagnosed with pituitary-dependent hyperadrenocorticism (a hormone disorder) may show symptoms like increased thirst, frequent urination, and a pot-bellied appearance. Two common medications for this condition are mitotane and trilostane. While mitotane has been used for a long time, it can have serious side effects, making trilostane a more appealing option for many veterinarians due to its simpler administration and fewer side effects. Both treatments can be effective, but it's important for pet owners to work closely with their vet to monitor their dog's health during treatment.
People also search for: dog Cushing's disease treatment · pituitary-dependent hyperadrenocorticism in dogs · trilostane side effects in dogs
Abstract
Pituitary-dependent hyperadrenocorticism is a common endocrine disorder in dogs in the United States. Once a diagnosis is established, a decision must be made whether or not to pursue treatment, and if so, which medication to use. Historically, mitotane (Lysodren, o,p'-DDD, Bristol-Myers Squibb, New York) has been the most commonly used treatment for medical management. Its use is complicated and comes with many potential side effects, making many practitioners wary of its use. Recently, trilostane has been proven to be an effective treatment of pituitary-dependent hyperadrenocorticism and is approved for use in other countries. Treatment with trilostane is somewhat simpler and the incidence of side effects seems to be less when compared with mitotane therapy. Either treatment can be a safe and effective method of treatment for pituitary-dependent hyperadrenocorticism when the practitioner and client are well educated regarding their use and an appropriate monitoring protocol is used.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/17542193/